Apple is quietly turning the smartwatch into a low-effort blood-pressure tripwire. The company confirmed this week that a new “hypertension notifications” feature — which uses the Apple Watch’s existing optical heart sensor and machine learning to flag signs of high blood pressure — has just been cleared by the U.S. Food and Drug Administration and will begin rolling out with watchOS 26 next week.

If you own a recent Apple Watch, you’ll probably see the new capability soon. Apple says hypertension notifications will appear with the watchOS 26 update, which arrives on September 15, and the feature will be available on Apple Watch Series 9 and later, and Apple Watch Ultra 2 and later. The company also says the feature will go live in more than 150 countries and regions.

Apple’s own spokesperson—Zaina Khachadourian—told reporters the FDA has cleared the technology, moving the company from “coming soon” to “coming next week.” That’s the regulatory green light Apple was waiting for after announcing the feature at its event last week.

How it actually works

This is important: the Watch is not becoming a traditional blood-pressure cuff. Instead, Apple’s hypertension notifications mine the Watch’s optical heart sensor for subtle signals about how your blood vessels respond to each heartbeat. An algorithm passively reviews that sensor data over rolling 30-day windows; if it detects a consistent pattern that looks like hypertension, it pushes a “possible hypertension” notification to the user.

Apple frames the feature as an early-warning system rather than a diagnostic test. The company says it trained the model on data from more than 100,000 participants and validated performance in a clinical study of over 2,000 people, and it expects the feature could notify more than 1 million people with previously undiagnosed hypertension in its first year.

Getting clearance from the FDA isn’t just PR — it matters because it means U.S. regulators reviewed the data Apple submitted and judged the algorithm’s performance acceptable for its intended use as a screening/notification tool. Reuters and other outlets reported the clearance on Friday, which opens the door for Apple to flip the switch for U.S. users immediately after the update. For Apple, regulatory clearance helps the company put health features front and center in product messaging and helps clinicians take those alerts more seriously.

If your Watch notifies you, Apple recommends a simple next step: log your blood pressure for seven days using a validated cuff-based monitor and share those readings with your clinician — advice that aligns with American Heart Association guidelines for diagnosing hypertension. In other words, treat the notification as a prompt to check, not as a final readout.

Physicians and researchers will likely welcome the extra data stream — hypertension is often silent and underdiagnosed — but they’ll also caution that wrist-based, sensor-inferred signals aren’t a replacement for clinical measurements. Independent reporting and medical commentary published alongside Apple’s launch stress that the Watch flags possible hypertension; definitive diagnosis still relies on proper cuff readings and clinical judgment.

The limitations

Apple’s documentation is explicit about the feature’s constraints: it’s designed as a screening tool, not a diagnostic device, and Apple lists groups for whom the feature isn’t intended (for example, people under a certain age or people already diagnosed and being treated for hypertension — see Apple’s full guidance). The algorithm looks for consistent patterns over time, so short bursts of elevated readings (stress, caffeine, a bad night’s sleep) are less likely to produce an alert than a sustained pattern.

There are also technical caveats: optical sensors can be sensitive to motion, skin tone, fit, and other variables; Apple’s training and validation studies aim to account for those factors, but real-world performance will vary across users. That’s why clinicians will still insist on cuff-based confirmation before changing medications or making diagnoses.

Apple’s push into blood-pressure screening is the next step in a long game: over the past decade, the Watch has moved from step counter to heart-monitoring platform — ECGs, irregular-rhythm detection, blood oxygen, sleep insights — and the company has steadily tried to make its sensors and software useful to clinicians as well as consumers. Policy and regulatory approvals help make those features more defensible in a healthcare context. If the Watch can reliably nudge undiagnosed people into clinical care, that’s a major public-health win.

What to expect over the next few weeks

WatchOS 26 lands on September 15; once it rolls out, you should see the hypertension notification options in the Health/Watch apps if your model is supported. Apple will likely monitor early usage closely — device metrics, how many users receive alerts, and whether alerts lead to follow-up cuff measurements and clinical diagnoses. Expect commentaries from clinicians and data scientists in the coming weeks as independent observers start to compare Watch alerts with cuff-based measurements in everyday settings.